首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1447638

血流感染检测市场- 按产品（仪器、试剂和消耗品）、样本类型（全血、血液培养）、技术（PCR、质谱、原位杂交）、最终用途（医院） - 全球预测，2024 年- 2032 年

Bloodstream Infection Testing Market - By Product (Instruments, Reagents & Consumables), Sample Type (Whole Blood, Blood Culture), Technology (PCR, Mass Spectroscopy, In Situ Hybridization), End-use (Hospitals) - Global Forecast, 2024 - 2032

出版日期: 2024年01月31日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在质谱和自动化血液培养系统等诊断技术和仪器进步的推动下，血流感染检测市场规模从 2024 年到 2032 年将以 4.9% 的CAGR成长。不断涌现的创新正在提供更快、更准确、更有效率的测试方法，以改善患者的治疗结果。此外，医疗保健公司之间合作开发新型检测解决方案将有助于市场扩张。先进技术与医疗保健领域的协作努力之间的协同作用也将有助于满足对血流感染准确及时诊断不断增长的需求。

例如，2023 年 11 月，Oxford Nanopore 和 Day Zero Diagnostics (DZD) 合作创建了一种诊断血流感染的综合解决方案，血流感染是导致败血症（一种危及生命的疾病）的主要原因。此次合作也提供了端到端的诊断解决方案，以提高患者的治疗效果。

血流感染检测产业分为样本类型、技术、最终用途和地区。

根据产品，到 2032 年，仪器领域的市占率CAGR将达到 4.5%。这是由于越来越多地采用自动化仪器来更快、更准确地检测血流感染。血液培养系统和分子诊断平台等仪器可以快速提供结果并改善患者的治疗效果。最近，仪器技术不断进步，例如灵敏度和特异性的增强。对早期和精确诊断的日益重视也将增加对仪器的需求。

到 2032 年，质谱技术领域的血流感染检测行业将以 4.9% 的CAGR大幅增长。这种增长是由质谱在识别病原体和确定抗生素抗药性方面的准确性和效率所推动的。质谱分析能够快速、全面地分析微生物蛋白质，有助于及时做出针对性的治疗决策。随着对精确可靠的感染检测方法的需求不断增长，质谱技术的应用不断增加。此外，临床实验室和医院越来越多地采用该技术将进一步推动该领域的成长。

由于传染病负担日益增加、人们对早期检测重要性的认识不断提高以及医疗基础设施的改善，2024年至2032年亚太地区血流感染检测行业份额的CAGR将达到5.2%。由于中国、印度和日本等国家人口众多，人们越来越关注医疗保健的进步。此外，对创新诊断技术不断增长的需求将进一步加强亚太地区作为血流感染检测市场主要贡献者的地位。

产业生态系统分析
产业影响力
- 成长动力
  - 传染病流行率不断上升
  - 血流感染检测的技术进步
  - 即时检测 (POCT) 设备的开发与采用
  - 提高对医疗保健相关感染 (HAI) 的认识和关注
- 产业陷阱与挑战
  - 现有测试的局限性
  - 初始设定和持续维护成本高昂
成长潜力分析
监管环境
技术景观
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
主要市场参与者的竞争分析
公司矩阵分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

主要趋势
试剂及耗材
仪器

第 6 章：市场估计与预测：按样本类型，2018 年 - 2032 年

主要趋势
全血
血液培养

第 7 章：市场估计与预测：按技术划分，2018 年 - 2032 年

主要趋势
聚合酶炼式反应
质谱分析
原位杂交
其他技术

第 8 章：市场估计与预测：按最终用途，2018 - 2032 年

主要趋势
医院和诊断中心
学术及研究机构
其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abbott Laboratories
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
bioMérieux SA
Bruker Corporation
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Luminex Corporation
Siemens Healthineers AG
Thermo Fisher Scientific Inc.

简介目录

Product Code: 7992

Bloodstream Infection Testing Market size will grow at 4.9% CAGR from 2024 to 2032, propelled by advancements in diagnostic technologies and instruments like mass spectrometry and automated blood culture systems. Rising innovations are offering faster, more accurate, and efficient testing methods for improving patient outcomes. Additionally, collaborations between healthcare companies for the development of novel testing solutions will contribute to the market expansion. The synergy between advanced technologies and collaborative efforts in the healthcare sector will also help meet the rising demand for precise and timely diagnosis of bloodstream infections.

For instance, in November 2023, Oxford Nanopore and Day Zero Diagnostics (DZD) collaborated to create a comprehensive solution for diagnosing bloodstream infections, a primary contributor to sepsis, a life-threatening condition. This partnership also offered an end-to-end diagnostic solution for enhanced patient outcomes.

The bloodstream infection testing industry is classified into sample type, technology, end-use, and region.

Based on product, the market share from the instruments segment will garner 4.5% CAGR up to 2032. This is due to the increasing adoption of automated instruments for faster and accurate detection of bloodstream infections. Instruments, such as blood culture systems and molecular diagnostic platforms, offer rapid results and improve patient outcomes. Lately, there have been rising advancements in instrument technology, such as enhanced sensitivity and specificity. The growing emphasis on early and precise diagnosis will also add to the demand for instruments.

Bloodstream infection testing industry from the mass spectroscopy technology segment will witness a substantial upswing at 4.9% CAGR through 2032. The growth is driven by the accuracy and efficiency of mass spectrometry in identifying pathogens and determining antibiotic resistance. Mass spectrometry enables rapid and comprehensive analysis of microbial proteins for aiding in timely and targeted treatment decisions. With the growing demand for precise and reliable infection testing methods, the deployment of mass spectroscopy is rising. Moreover, increasing adoption in clinical laboratories and hospitals will further propel the segment growth.

Asia Pacific bloodstream infection testing industry share will register a 5.2% CAGR from 2024 to 2032, owing to the increasing burden of infectious diseases, rising awareness about the importance of early detection, and improving healthcare infrastructure. With the large population in countries like China, India, and Japan, there is a growing focus on healthcare advancements. Additionally, the rising demand for innovative diagnostic technologies will further strengthen Asia Pacific's position as a key contributor in the bloodstream infection testing market.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of infectious diseases
  - 3.2.1.2 Technological advancements in bloodstream infection testing
  - 3.2.1.3 Development and adoption of point-of-care testing (POCT) devices
  - 3.2.1.4 Increased awareness and focus on healthcare-associated infections (HAIs)
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limitations of the existing tests
  - 3.2.2.2 High initial setup and ongoing maintenance costs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Competitive analysis of major market players
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Reagents & consumables
5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Sample Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Whole blood
6.3 Blood culture

Chapter 7 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 PCR
7.3 Mass spectroscopy
7.4 In situ hybridization
7.5 Other technologies

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals & diagnostic centers
8.3 Academic & research institutes
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa